Cell Signaling Technology

Product Pathways - NF-kB Signaling

NALP1 Antibody #4990

Applications Reactivity Sensitivity MW (kDa) Source
W H M R (Mk) Endogenous 165, 70 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human  M=Mouse  R=Rat  Mk=Monkey
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

NALP1 Antibody detects endogenous levels of total NALP1 protein. This antibody also detects a 70 kDa protein that correlates with a predicted short form (NALP1s) that lacks the leucine repeat region (7).

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide that corresponds to a region surrounding Gly1081 of human NALP1 protein. Antibodies were purified by peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from K-562 and SH-SY5Y cells and from rat testis using NALP1 Antibody.

Background

NALP1 (DEFCAP/NAC/CARD7) is an NLR (Nod-like receptor) family member that has been implicated in the regulation of apoptosis and inflammatory responses (1-5). Structurally, NALP contains an amino-terminal PYRIN domain, followed by a nucleotide-binding site (NBS), a leucine rich repeat region (LRR), and a carboxy-terminal CARD domain. NALP1 and interacts strongly with caspase-2 and weakly with caspase-9, and induces apoptosis when overexpressed (3). Similar to a related Ced-4 family member Apaf-1, it was also shown to be involved in cytochrome c-dependent caspase activation (2). It has also been shown to be part of the "inflammasome" comprised of caspase-1, caspase-5, and Pycard/ASC, which is critical in the processing of pro-inflammatory cytokines like IL-1β (6). Two major isoforms were identified for NALP1, which differ in a 44 amino acid region within the LRR (3). In addition, like NALP3, a short NALP1 isoform lacking the LRR (NALP1s) likely exists (7). Polymorphisms in NALP1 have been associated with autoimmune disease (8) and susceptibility to toxins (9).

  1. Bertin, J. and DiStefano, P.S. (2000) Cell Death Differ. 7, 1273-1274.
  2. Chu, Z.L. et al. (2001) J. Biol. Chem. 276, 9239-9245.
  3. Hlaing, T. et al. (2001) J. Biol. Chem. 276, 9230-9238.
  4. Martinon, F. et al. (2001) Curr. Biol. 11, R118-R120.
  5. Fritz, J.H. et al. (2006) Nat. Immunol. 7, 1250-1257.
  6. Martinon, F. et al. (2002) Mol. Cell 10, 417-426.
  7. Kummer, J.A. et al. (2007) J. Histochem. Cytochem. 55, 443-452.
  8. Jin, Y. et al. (2007) N. Engl. J. Med. 356, 1216-1225.
  9. Boyden, E.D. and Dietrich, W.F. (2006) Nat. Genet. 38, 240-244.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products